Platelets Treated with Ticlopidine Are Less Reactive to Unusually Large von Willebrand Factor Multimers than Are Those Treated with Aspirin under High Shear Stress
Open Access
- 1 November 2005
- journal article
- case report
- Published by S. Karger AG in Pathophysiology of Haemostasis and Thrombosis
- Vol. 34 (1), 35-40
- https://doi.org/10.1159/000088546
Abstract
Much attention has recently been focused on the interaction between unusually large von Willebrand factor multimers (UL-VWFM) and platelets under high shear stress in pathological thrombus formation. The antiplatelet drugs acetylsalicylic acid (aspirin) and a thienopyridine derivative (ticlopidine) are commonly used to treat cerebral ischemia but exert different effects on high-shear-stress-induced platelet aggregation (H-SIPA) in the plasma. To examine the effects of these drugs in the absence of plasma factors, we studied H-SIPA using washed platelets (WPs) and purified UL-VWFM. WPs were prepared from the blood of 9 aspirin-treated and 11 ticlopidine-treated patients with cerebral ischemia, and H-SIPA in the presence of UL-VWFM was measured using a cone plate aggregometer. Plasma levels of VWF antigen with its multimer analysis, ristocetin cofactor and VWF-cleaving protease (ADAMTS13) activity were also measured. Forty-six healthy volunteers from 2 age groups, 20–40 years (n = 20) and 41–60 years old (n = 26), were also tested as controls. H-SIPA was significantly inhibited for ticlopidine-treated platelets, but it was observed to a lesser extent for aspirin-treated platelets. For both groups, no difference in the plasma levels of VWF antigen, ristocetin cofactor and ADAMTS13 activity was noted. All patients possessed UL-VWFM, and it was detected in healthy volunteers with increasing frequency with increasing age. Under plasma-free conditions, platelets from aspirin-treated patients exhibit marginal but significant inhibition of H-SIPA. Furthermore, the presence of UL-VWFM in the plasma of patients and normal volunteers is directly related to their age rather than being a consequence of underlying disease.Keywords
This publication has 19 references indexed in Scilit:
- Antiplatelet Effect of Aspirin in Patients With Cerebrovascular DiseaseStroke, 2004
- Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y 12 ) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ibα Induced by Conditions of High Shear RateCirculation, 2002
- Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugsJCI Insight, 2001
- Ticlopidine and ClopidogrelCirculation, 1999
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Shear-induced platelet aggregation in cerebral ischemia.Stroke, 1994
- The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.JCI Insight, 1991
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.JCI Insight, 1986
- Variant von Willebrand's DiseaseJCI Insight, 1980
- Factor-VIII-related antigen: measurement by enzyme immunoassay.BMJ, 1976